Company logo

LPCN - Lipocine Inc.

NASDAQ -> Healthcare -> Biotechnology
Salt Lake City, United States
Type: Equity
LPCN price evolution
LPCN
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Current assets
Cash $5.55 $3.08 $4.77
Short term investments $17 $21.55 $17.26
Net receivables $0.09 $0.06 $0.1 $0.05
Inventory
Total current assets $20.5 $22.91 $25.32 $22.86
Long term investments
Property, plant & equipment $0.17 $0.1 $0.11 $0.12
Goodwill & intangible assets
Total noncurrent assets $0.12 $0.13 $0.14
Total investments $17 $21.55 $17.26
Total assets $20.7 $23.03 $25.45 $23
Current liabilities
Accounts payable $0.29 $0.45 $0.67 $1.4
Deferred revenue
Short long term debt
Total current liabilities $1.58 $1.82 $1.49 $2.63
Long term debt
Total noncurrent liabilities
Total debt
Total liabilities $1.58 $1.82 $1.49 $2.63
Shareholders' equity
Retained earnings -$201.55 -$199.33 -$196.26 -$199.78
Other shareholder equity $0.01 -$0.01 -$0.01 $0.01
Total shareholder equity $21.21 $23.96 $20.37
(in millions $) 31 Dec 2023 31 Jan 2023 31 Dec 2021 31 Dec 2020
Current assets
Cash $4.77 $3.15 $2.95 $24.22
Short term investments $17.26 $29.38 $41.67 $0.45
Net receivables $0.05 $0.08 $0.25 $0
Inventory
Total current assets $22.86 $34.14 $46.38 $25.33
Long term investments $2.02
Property, plant & equipment $0.12 $0.13 $0.01
Goodwill & intangible assets
Total noncurrent assets $0.14 $3.41 $6.1 $0.02
Total investments $17.26 $29.38 $43.69 $0.45
Total assets $23 $37.54 $52.48 $25.35
Current liabilities
Accounts payable $1.4 $0.6 $1.29 $1.6
Deferred revenue
Short long term debt $2.31 $3.33
Total current liabilities $2.63 $1.68 $5.62 $6.58
Long term debt $2.26
Total noncurrent liabilities $0.23 $1.3 $3.43
Total debt $2.31 $5.59
Total liabilities $2.63 $1.91 $6.91 $10.01
Shareholders' equity
Retained earnings -$199.78 -$183.43 -$172.67 -$172.03
Other shareholder equity $0.01 -$0.02 -$0.02 -$0.04
Total shareholder equity $20.37 $35.63 $45.57 $15.34
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Revenue
Total revenue $0.09 $7.62 $0.22
Cost of revenue
Gross Profit $0.09 $7.62 $0.22
Operating activities
Research & development $1.87 $2.82 $1.67
Selling, general & administrative $1.51 $1.58 $1.13
Total operating expenses $3.38 $4.39 $2.81
Operating income -$3.29 $3.22 -$2.59
Income from continuing operations
EBIT -$3.07 $3.51 -$2.28
Income tax expense $0 $0 $0
Interest expense
Net income
Net income -$3.07 $3.51 -$2.28
Income (for common shares) -$3.07 $3.51 -$2.28
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Revenue
Total revenue -$2.85 $0.5 $16.14
Cost of revenue
Gross Profit -$2.85 $0.5 $16.14
Operating activities
Research & development $10.18 $8.56 $7.67 $9.75
Selling, general & administrative $4.9 $4.06 $5.33 $8.25
Total operating expenses $15.08 $12.62 $13 $18
Operating income -$17.93 -$12.12 $3.15 -$18
Income from continuing operations
EBIT -$16.35 -$10.73 -$0.43 -$20.58
Income tax expense $0 $0 $0 $0
Interest expense $0.03 $0.2 $0.39
Net income
Net income -$16.35 -$10.76 -$0.63 -$20.96
Income (for common shares) -$16.35 -$10.76 -$0.63 -$20.96
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Net income -$3.07 $3.51 -$2.28
Operating activities
Depreciation $0.01 $0.01 $0.01
Business acquisitions & disposals
Stock-based compensation $0.1 $0.1 $0.15
Total cash flows from operations -$2.5 $2.41 -$2.02
Investing activities
Capital expenditures -$0.01
Investments $4.75 -$4.09 $2.74
Total cash flows from investing $1.69 $4.75 -$4.09 $2.73
Financing activities
Dividends paid
Sale and purchase of stock $0.21 -$0.01
Net borrowings
Total cash flows from financing $0.21 $0.22 -$0.01 -$0.01
Effect of exchange rate
Change in cash and equivalents -$1.03 $2.47 -$1.69 $0.7
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income -$16.35 -$10.76 -$0.63 -$20.96
Operating activities
Depreciation $0.03 $0.01 $0 $0
Business acquisitions & disposals
Stock-based compensation $0.65 $0.64 $0.6 $1.37
Total cash flows from operations -$11.87 -$11.97 -$4.41 -$15.3
Investing activities
Capital expenditures -$0.01 -$0.13 -$0.01
Investments $13.1 $14.43 -$43.77 $3.89
Total cash flows from investing $13.08 $14.29 -$43.78 $3.89
Financing activities
Dividends paid
Sale and purchase of stock $0.4 $0.19 $30.26 $22.33
Net borrowings -$2.32 -$3.33 -$1.43
Total cash flows from financing $0.4 -$2.13 $26.92 $20.9
Effect of exchange rate
Change in cash and equivalents $1.62 $0.2 -$21.27 $9.49
News
Is Lipocine Inc.'s (NASDAQ:LPCN) Stock's Recent Performance Being Led By Its Attractive Financial...
Simply Wall St. via Yahoo Finance 16 Jan 2023
Lipocine To Focus On Central Nervous System Conditions; Explores Partnerships For Non-Core Assets
Benzinga via Yahoo Finance 26 Sep 2022
Lipocine Inc. (NASDAQ:LPCN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market...
Simply Wall St. via Yahoo Finance 8 Aug 2022
Lipocine Posts Encouraging Data For Testosterone Prodrug In NASH Patients
Benzinga via Yahoo Finance 13 May 2022
Shareholders in Lipocine (NASDAQ:LPCN) are in the red if they invested five years ago
Simply Wall St. via Yahoo Finance 4 May 2022
53 Biggest Movers From Yesterday
Benzinga 30 Mar 2022
36 Stocks Moving In Tuesday's Mid-Day Session
Benzinga 29 Mar 2022
20 Stocks Moving in Tuesday's Pre-Market Session
Benzinga 29 Mar 2022
Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates
Benzinga 2 Mar 2022
The Daily Biotech Pulse: Lilly Strikes Neurological R&D Collaboration, Valneva Confirms Vaccine...
Benzinga 6 Jan 2022
Fundamentals
Market cap $26.04M
Enterprise value N/A
Shares outstanding 5.35M
Revenue N/A
EBITDA N/A
EBIT N/A
Net Income N/A
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio N/A
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio N/A
P/B ratio N/A
Book/Share N/A
Cash/Share N/A
EPS N/A
ROA N/A
ROE N/A
Debt/Equity 0.13
Net debt/EBITDA N/A
Current ratio 12.97
Quick ratio N/A

Copyright Statfolio @ 2024

Social Accounts